Intellia Therapeutics price target lowered to $111 from $129 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Intellia Therapeutics to $111 from $129 and keeps a Buy rating on the shares. The firm said that, with greater visibility on tech capabilities and strategies from emerging public and private GE players, it continues to expect increasing competition on in vivo approaches to rare disease, accordingly trims its valuation for Intellia’s in vivo platform.